Entropy Technologies LP bought a new position in shares of Amedisys, Inc. (NASDAQ:AMED – Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,081 shares of the health services provider’s stock, valued at approximately $378,000.
A number of other hedge funds have also recently added to or reduced their stakes in AMED. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Amedisys by 56.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider’s stock worth $31,000 after acquiring an additional 120 shares during the period. Fifth Third Bancorp increased its position in Amedisys by 68.1% during the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock worth $32,000 after purchasing an additional 141 shares during the last quarter. Gamco Investors INC. ET AL increased its position in Amedisys by 0.5% during the fourth quarter. Gamco Investors INC. ET AL now owns 30,334 shares of the health services provider’s stock worth $2,754,000 after purchasing an additional 159 shares during the last quarter. Hexagon Capital Partners LLC raised its stake in Amedisys by 108.1% during the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider’s stock worth $29,000 after purchasing an additional 161 shares during the period. Finally, UMB Bank n.a. boosted its holdings in shares of Amedisys by 100.0% in the 1st quarter. UMB Bank n.a. now owns 386 shares of the health services provider’s stock valued at $36,000 after purchasing an additional 193 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts recently commented on the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Wall Street Zen downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 24th.
Amedisys Price Performance
Shares of NASDAQ AMED opened at $100.98 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.36 and a quick ratio of 1.36. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $101.01. The company has a market capitalization of $3.32 billion, a price-to-earnings ratio of 39.29, a PEG ratio of 1.34 and a beta of 0.89. The business has a 50-day moving average of $97.73 and a 200-day moving average of $94.61.
Amedisys (NASDAQ:AMED – Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.15. Amedisys had a return on equity of 12.91% and a net margin of 3.56%. The firm had revenue of $621.86 million during the quarter, compared to analysts’ expectations of $614.61 million. During the same quarter in the prior year, the business earned $0.98 EPS. Amedisys’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also
- Five stocks we like better than Amedisys
- How Can Investors Benefit From After-Hours Trading
- 3 Earnings Reports Give a Snapshot of Consumer Sentiment
- 5 discounted opportunities for dividend growth investors
- Amazon’s Bears Have Raised the White Flag—Get Excited
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.